Skip to main content
NCBI home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1989 Sep;135(3):427–433.

Interleukin-6 immunoreactivity in human tumors.

S S Tabibzadeh 1, D Poubouridis 1, L T May 1, P B Sehgal 1
PMCID: PMC1879877  PMID: 2675620

Abstract

The cytokine, interleukin-6 (IL-6), has emerged as a likely mediator of many of the systemic alterations observed in patients with cancer (fever, increased erythrocyte sedimentation rate, and alterations in plasma protein composition) and may also mediate local effects such as alteration in proliferation of tumor cells, increased tumor cell motility, and decreased intercellular adhesions between tumor cells. The distribution of IL-6 immunoreactivity in different human tumors was studied. IL-6 immunoreactivity was detected by the avidin-biotin-complex (ABC) procedure using a polyclonal rabbit antiserum raised against an E coli-derived human IL-6 (rIL-6). Preimmune rabbit serum used as a control did not yield specific staining and preadsorption of the IL-6 antiserum with rIL-6 abolished specific staining. Strong-to-moderate IL-6 immunoreactivity was observed in the neoplastic elements present in primary squamous cell carcinomas, in adenocarcinomas of mammary, colonic, ovarian, and endometrial origin, in various adenocarcinomas metastatic to lymph nodes, and in soft tissue tumors including leiomyosarcoma and neurofibrosarcoma. Weak-to-moderate IL-6 immunostaining was observed in Hodgkin's and non-Hodgkin's lymphomas. This study demonstrates that most human tumors stain positively for IL-6, adding weight to the hypothesis that IL-6 is a key cytokine that participates in the host-tumor interaction.

Full text

PDF
427

Images in this article

429Figure 1
on p.429
430Figure 2
on p.430
431Figure 3
on p.431

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bedell S. E., Bush B. T. Erythrocyte sedimentation rate. From folklore to facts. Am J Med. 1985 Jun;78(6 Pt 1):1001–1009. doi: 10.1016/0002-9343(85)90224-4. [DOI] [PubMed] [Google Scholar]
  2. Chen L., Mory Y., Zilberstein A., Revel M. Growth inhibition of human breast carcinoma and leukemia/lymphoma cell lines by recombinant interferon-beta 2. Proc Natl Acad Sci U S A. 1988 Nov;85(21):8037–8041. doi: 10.1073/pnas.85.21.8037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Fong Y., Moldawer L. L., Marano M., Wei H., Tatter S. B., Clarick R. H., Santhanam U., Sherris D., May L. T., Sehgal P. B. Endotoxemia elicits increased circulating beta 2-IFN/IL-6 in man. J Immunol. 1989 Apr 1;142(7):2321–2324. [PubMed] [Google Scholar]
  4. Gelin J., Moldawer L. L., Lonnroth C., deMan P., Svanborg-Eden C., Lowry S. F., Lundholm K. G. Appearance of hybridoma growth factor/interleukin-6 in the serum of mice bearing a methylcholanthrene-induced sarcoma. Biochem Biophys Res Commun. 1988 Dec 15;157(2):575–579. doi: 10.1016/s0006-291x(88)80288-2. [DOI] [PubMed] [Google Scholar]
  5. Helfgott D. C., Tatter S. B., Santhanam U., Clarick R. H., Bhardwaj N., May L. T., Sehgal P. B. Multiple forms of IFN-beta 2/IL-6 in serum and body fluids during acute bacterial infection. J Immunol. 1989 Feb 1;142(3):948–953. [PubMed] [Google Scholar]
  6. Hirano T., Taga T., Yasukawa K., Nakajima K., Nakano N., Takatsuki F., Shimizu M., Murashima A., Tsunasawa S., Sakiyama F. Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production. Proc Natl Acad Sci U S A. 1987 Jan;84(1):228–231. doi: 10.1073/pnas.84.1.228. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hsu S. M., Raine L., Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981 Apr;29(4):577–580. doi: 10.1177/29.4.6166661. [DOI] [PubMed] [Google Scholar]
  8. Jablons D. M., McIntosh J. K., Mulé J. J., Nordan R. P., Rudikoff S., Lotze M. T. Induction of interferon-beta 2/interleukin-6 (IL-6) by cytokine administration and detection of circulating interleukin-6 in the tumor-bearing state. Ann N Y Acad Sci. 1989;557:157–161. doi: 10.1111/j.1749-6632.1989.tb24008.x. [DOI] [PubMed] [Google Scholar]
  9. Jablons D. M., Mulé J. J., McIntosh J. K., Sehgal P. B., May L. T., Huang C. M., Rosenberg S. A., Lotze M. T. IL-6/IFN-beta-2 as a circulating hormone. Induction by cytokine administration in humans. J Immunol. 1989 Mar 1;142(5):1542–1547. [PubMed] [Google Scholar]
  10. Kawano M., Hirano T., Matsuda T., Taga T., Horii Y., Iwato K., Asaoku H., Tang B., Tanabe O., Tanaka H. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 1988 Mar 3;332(6159):83–85. doi: 10.1038/332083a0. [DOI] [PubMed] [Google Scholar]
  11. Klein B., Zhang X. G., Jourdan M., Content J., Houssiau F., Aarden L., Piechaczyk M., Bataille R. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood. 1989 Feb;73(2):517–526. [PubMed] [Google Scholar]
  12. May L. T., Ghrayeb J., Santhanam U., Tatter S. B., Sthoeger Z., Helfgott D. C., Chiorazzi N., Grieninger G., Sehgal P. B. Synthesis and secretion of multiple forms of beta 2-interferon/B-cell differentiation factor 2/hepatocyte-stimulating factor by human fibroblasts and monocytes. J Biol Chem. 1988 Jun 5;263(16):7760–7766. [PubMed] [Google Scholar]
  13. May L. T., Santhanam U., Tatter S. B., Bhardwaj N., Ghrayeb J., Sehgal P. B. Phosphorylation of secreted forms of human beta 2-interferon/hepatocyte stimulating factor/interleukin-6. Biochem Biophys Res Commun. 1988 May 16;152(3):1144–1150. doi: 10.1016/s0006-291x(88)80404-2. [DOI] [PubMed] [Google Scholar]
  14. Sehgal P. B., May L. T., Tamm I., Vilcek J. Human beta 2 interferon and B-cell differentiation factor BSF-2 are identical. Science. 1987 Feb 13;235(4790):731–732. doi: 10.1126/science.3492764. [DOI] [PubMed] [Google Scholar]
  15. Tabibzadeh S. S., Bettica A., Gerber M. A. Variable expression of Ia antigens in human endometrium and in chronic endometritis. Am J Clin Pathol. 1986 Aug;86(2):153–160. doi: 10.1093/ajcp/86.2.153. [DOI] [PubMed] [Google Scholar]
  16. Tabibzadeh S. S., Gerber M. A. Applicability of imprints to immuno-ultrastructural studies of lymphoid tissues. J Histochem Cytochem. 1985 Sep;33(9):884–890. doi: 10.1177/33.9.2410482. [DOI] [PubMed] [Google Scholar]
  17. Tabibzadeh S. S., Gerber M. A. Immunohistologic analysis of lymphoid cells by a rapid double staining method. J Immunol Methods. 1986 Jul 24;91(2):169–174. doi: 10.1016/0022-1759(86)90475-8. [DOI] [PubMed] [Google Scholar]
  18. Tabibzadeh S. S., Mortillo S., Gerber M. A. Immunoultrastructural localization of Ia antigens in human endometrium. Arch Pathol Lab Med. 1987 Jan;111(1):32–37. [PubMed] [Google Scholar]
  19. Tabibzadeh S. S., Santhanam U., Sehgal P. B., May L. T. Cytokine-induced production of IFN-beta 2/IL-6 by freshly explanted human endometrial stromal cells. Modulation by estradiol-17 beta. J Immunol. 1989 May 1;142(9):3134–3139. [PubMed] [Google Scholar]
  20. Tosato G., Seamon K. B., Goldman N. D., Sehgal P. B., May L. T., Washington G. C., Jones K. D., Pike S. E. Monocyte-derived human B-cell growth factor identified as interferon-beta 2 (BSF-2, IL-6). Science. 1988 Jan 29;239(4839):502–504. doi: 10.1126/science.2829354. [DOI] [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES